Suzhou Fushilai Pharmaceutical Co. Ltd.

Fushilai released its 2026 interim report, with net profit attributable to the parent company at negative 14.6171 million yuan, swinging from profit to loss. The company's total operating revenue was 185 million yuan, down 17.17% year-on-year; net cash flow from operating activities was negative 26.7376 million yuan, down 154.91% year-on-year. The company's latest asset-liability ratio was 10.17%, gross margin was 14.00%, ROE was negative 0.80%, and diluted earnings per share was negative 0.17 yuan.

Fujilai released its 2026 interim report. First-half operating revenue was 185 million yuan, down 17.2% year on year, with a loss of 14.62 million yuan, down 133.9% year on year. Excluding non-recurring items, the loss was 20.07 million yuan, down 380.2% year on year. Net operating cash flow was negative 26.74 million yuan, down 154.9% year on year, and earnings per share were negative 0.165 yuan. Second-quarter operating revenue was 92.61 million yuan, down 16.4% year on year, and net profit attributable to the parent company showed a loss of 11.85 million yuan, down 161.9% year on year. The company said the decline was mainly affected by overseas market inflation and reduced customer demand. Alpha-lipoic acid series products account for a relatively high share of revenue, and there is a risk from changes in the market environment.